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Background: To assess the change in rates of pediatric real-time or intermittent scanning continuous glucose monitoring (CGM) use over the past 5 years, and how it impacts glycemic control, data from two registries were compared: the US-based type 1 diabetes Exchange Registry (T1DX) and the German/Austrian DPV (Prospective Diabetes Follow-Up Registry). Results: CGM use increased from 2011 to 2016 in both registries across all age groups, regardless of gender, ethnic minority status or insulin delivery method. The increase in CGM use was most pronounced in the youngest patients, and usage rates remain lowest for adolescent patients in 2016. For both registries in 2016, mean HbA1c was lower among CGM users regardless of insulin delivery method compared to pump only (P < 0.001) and injection only (P < 0.001), and CGM users were more likely to achieve glycemic target of HbA1c <7.5% (56% vs 43% for DPV and 30% vs 15% for T1DX, P < 0.001). T1DX participants had a higher mean HbA1c compared with DPV despite whether they were CGM users or non-users; however, the difference was less pronounced in CGM users (P < 0.001).
Conclusions: Pediatric CGM use increased in both registries and was associated with lower mean HbA1c regardless of insulin delivery modality.
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| INTRODUCTION
The goal of diabetes management in children and adolescents with type 1 diabetes (T1D) is to achieve tight glycemic control to prevent acute and chronic complications; however, youth often fail to meet hemoglobin A1c (HbA1c) targets.
1,2 Growing evidence shows the benefit of continuous glucose monitoring (CGM) as a basis for improving glycemic control in those who wear the CGM device almost daily. [3] [4] [5] Although the potential benefits of CGM are well known to clinicians, the actual rates of CGM device use in T1D youth in prior studies have been low. In an earlier study of the T1D Exchange Registry (T1DX), only 6% of children <13 years and 4% of adolescents 13 to <18 years were using CGM. 6 Previously, DPV (Prospective Diabetes Follow-Up Registry) data were used to compare pump and injection users. 7 In the DPV regis- highlighted the challenge of CGM use in adolescents and young adults.
After 6 months, only 30% of the adolescents and young adults (15-24 years) were using CGM 6 or more days per week compared to 83% of adults aged 25 years or older. However, among those who were using CGM on a daily or near-daily basis, improvement in glycemic control was similar, independent of age group.
Over the past 10 years, the accuracy 8 and usability of CGM devices has improved considerably, which may be accompanied by an increase in CGM use, and associated improvement in glycemic control. To assess this, we analyzed data from the US T1DX and German/Austrian DPV registries to assess the increase in CGM use over the past 5 years, compare current CGM use between registries, and compare glycemic control (HbA1c %) between current CGM users and non-users.
| METHODS
We analyzed T1DX Registry and DPV Initiative participants aged and from 3% to 22% in the T1DX Registry (P < 0.001). CGM use increased for all age groups in both registries, and was most pronounced in the youngest patients (1 to <6 years) with an increase from 6% to 28% for DPV and 4% to 45% for T1DX. Although CGM Mean HbA1c in DPV vs T1DX according to CGM use and age group for the more recent 2016 data is shown in Figure 1 . T1DX participants had a higher mean HbA1c compared with DPV despite whether they were CGM users or non-users. However, the difference between mean HbA1c in DPV vs T1DX was less pronounced in CGM users (P < 0.001) (Figure 1 ). In 2016, mean HbA1c was lower among CGM users regardless of insulin delivery method compared to pump only (P < 0.001) and injection only (P < 0.001) in both T1DX and DPV registries ( Figure 1B) . Additionally, CGM users were more likely to achieve glycemic targets (HbA1c < 7.5% [<58 mmol/mol]) for both DPV (56% vs 43%, P < 0.001) and T1DX (30% vs 15%, P < 0.001) registries in 2016. 
| DISCUSSION

